Reason for request
- Re-assessment of the improvement in actual benefit at the applicant’s
Clinical Benefit
Clinical Added Value
| minor |
Au regard des nouvelles données disponibles, l’ipilimumab (YERVOY) conserve son amélioration du service médical rendu mineure (ASMR IV) dans la stratégie thérapeutique. |
eNq9WF1v2jAUfedXRHnPF10HnQLVxtoNqVUZLdq0l8okFzBz7NQfFPbr5xC60clRW1P3BQnbOffa9/jcI6en64J4K+ACM9rzkzD2PaAZyzGd9/zJzXnQ9U/7rXSJVmhvWSeMw6TtexlBQvT8ajacAqIi/HF58Rn098D9fstL2XQJmXy0TklMwq9ILC5RWa3x0hXDuVeAXLC855dKbke9VEius+jfM/5LlCiDNNqN7M8ub9/tj6dRBfYMVCWAXyA6N4ICtcLMFOdA5QBJmDO+acj3yAobizEIpngGIyQXI85WOIfcGGKGiACrILP7/Br4ioCsghjBo2VWCCtwtETrMdwNzUl/1LMDuZZBHCSdTjvunHTjdhx3rELxvaMyV0FvIspuk06ctLtHEdBoo/fNNkEBBFFWQNAG/UPwnEKAS0xwoQo0tazciHGJiKOaYTF4TDtHcTjcPcmNHIuSoE24FKXtUSGO9DRwLQ7uNlLt4IZruSL6zP7Dp4qQ6IVZT3Zi4ijjSqsGTFHZoCnnY9uDGDAqYd1cUTsZlOsdFzGI14P9zai5BYzUlODMVvC0JCkQcjIeNuvd20nFJyRgwt1pxXdMc3YvXl+D9mvuKPtyK6NG0JLnyW37pPs+OT62vmI/NcEautOZ4qyESKsTFoeIzpDO2KFyozlrhnpg7BuRdeugWIYINHiowFKXNEsfLJ+ze+DujtUTRtAvZze25PmmgG+ut3+N0Djv/S27nWi76ASaqo2Jv5z49f134q4VN+vKQspSfIiiBRKBQPqEwhl/446w16LduX4nPqD2RbWqOkp9WrfL59fO9v495RIOdb6773cO2xhDcgUH1KGWameCOjx7fY3+Z3udpT16pCnuwmwtKpKYUVfmSE2NiId1BV1Xes61OFzNZrjhBaaRl2lUv/70W2lUvfz0W38AbZYO+Q==
2L2cjnBSqsxswkR1
